Akari CEO resigns over allegations of spending company funds

pharmafile | May 11, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akari, appointment 

Akari has lost its second CEO in 12 months after David Horn Solomon was accused of misusing the company credit card for personal purchases, it has been revealed; he resigned following an investigation by Akari and an independent law firm.

The magnitude of this misspending has not been confirmed, but the company did note that it considered them to be immaterial to its operations.

Horn Solomon’s predecessor, Gur Roshwalb, also quit the company amid controversy last year, after he was found to have contravened Akari policy and had approved false claims concerning one of the Phase 2 trials for its drug Coversin.  

His vacated role will be filled on a temporary basis by COO and board member Clive Richardson until a full-time replacement can be found.

Horn Solomon had previously served as CEO of Zealand Pharma between 2008 and 2015, before joining Akari at the end of August 2017.

Related Content


Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …


Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …


Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content